Can Fite Biopharma Ltd ADR (CANF) — Cash Flow-to-Debt Ratio
Can Fite Biopharma Ltd ADR (CANF) has a Cash Flow-to-Debt Ratio of -0.67x as of June 2025, meaning its operating cash flow of $-2.38 Million could theoretically repay -1% of its total liabilities ($3.54 Million) in one year. See CANF FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Can Fite Biopharma Ltd ADR Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Can Fite Biopharma Ltd ADR across 15 annual periods. For the full cash flow conversion analysis, see Can Fite Biopharma Ltd ADR cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Can Fite Biopharma Ltd ADR (2011–2025)
Year-by-year debt coverage analysis for Can Fite Biopharma Ltd ADR. Check earnings quality score of Can Fite Biopharma Ltd ADR to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.30x | $-9.02 Million | $3.92 Million | ▼ -10.9% |
| 2024 | -2.07x | $-7.64 Million | $3.68 Million | ▲ +8.0% |
| 2023 | -2.25x | $-8.44 Million | $3.75 Million | ▼ -0.4% |
| 2022 | -2.25x | $-10.80 Million | $4.81 Million | ▼ -33.7% |
| 2021 | -1.68x | $-9.86 Million | $5.87 Million | ▲ +52.0% |
| 2020 | -3.50x | $-12.06 Million | $3.45 Million | ▼ -85.0% |
| 2019 | -1.89x | $-10.83 Million | $5.73 Million | ▼ -124.6% |
| 2018 | -0.84x | $-4.16 Million | $4.94 Million | ▲ +57.8% |
| 2017 | -1.99x | $-9.52 Million | $4.78 Million | ▼ -40.5% |
| 2016 | -1.42x | $-8.93 Million | $6.29 Million | ▼ -118.2% |
| 2015 | -0.65x | $-4.65 Million | $7.16 Million | ▲ +70.5% |
| 2014 | -2.20x | $-7.33 Million | $3.33 Million | ▲ +44.5% |
| 2013 | -3.97x | $-8.63 Million | $2.18 Million | ▼ -113.7% |
| 2012 | -1.86x | $-4.35 Million | $2.34 Million | ▲ +45.6% |
| 2011 | -3.41x | $-5.50 Million | $1.61 Million | — |